Table 3.

Hazard Ratios of BRAF V600E or TERT C228T or Their Coexistence for the Recurrence of PTC

Type of PTC	Mutations	Recurrence	%	Recurrence per 1,000 Person-Years	95% CI	Unadjusted		Adjustment 1*		Adjustment 2†
						Hazard Ratios	95% CI	Hazard Ratios	95% CI	Hazard Ratios	95% CI
All PTC	No mutation	25 of 287	8.7	21.60	14.59 to 31.97	1.00				1.00
	BRAF mutation only	26 of 159	16.3	48.96	33.34 to 71.91	2.24	1.29 to 3.88	2.16	1.24 to 3.75	1.17	0.62 to 2.20
	TERT mutation only	5 of 26	19.2	32.50	13.53 to 78.09	1.69	0.65 to 4.43	1.60	0.60 to 4.25	0.87	0.27 to 2.76
	BRAF + TERT mutations	24 of 35	68.6	211.76	141.94 to 315.94	8.51	4.84 to 14.97	8.41	4.44 to 15.94	3.10	1.24 to 7.75
CPTC	No mutation	18 of 200	9.0	22.23	14.00 to 35.28	1.00				1.00
	BRAF mutation only	22 of 136	16.2	50.25	33.08 to 76.31	2.20	1.18 to 4.11	2.06	1.10 to 3.86	1.03	0.49 to 2.15
	TERT mutation only	4 of 19	21.0	35.22	13.22 to 93.83	1.82	0.61 to 5.38	1.71	0.56 to 5.22	0.50	0.12 to 2.00
	BRAF + TERT mutations	20 of 28	71.4	191.85	123.77 to 297.36	7.73	4.07 to 14.67	7.50	3.71 to 15.17	4.39	1.42 to 13.54

NOTE. Hazard ratios and 95% CIs were calculated using Cox regression for the comparison of the indicated mutation group with the group harboring neither mutation.

Abbreviations: CPTC, conventional papillary thyroid cancer; PTC, papillary thyroid cancer.

^*Adjustment 1 was made for patient age at diagnosis and sex.

^†Adjustment 2 was made for patient age at diagnosis, sex, multifocality, tumor size, extrathyroidal invasion, vascular invasion, and lymph node metastasis.